Register for the New York Pharma Forum Summer Social aboard the Intrepid with CEOs sharing their business wish lists ...
Continue reading "Register for the New York Pharma Forum" »
As governments around the world grapple with the challenge of reforming their ailing healthcare systems, China has moved faster and further than most...
Continue reading "FT China Healthcare and Life Sciences Summit" »
It is clear that the pharmaceutical industry needs to evolve, but in which direction and how quickly? One thing is certain: Rewards will be great for companies that tap into new opportunities and align their business models and strategies for the future. In this
complimentary webinar (Thursday, June 24), pharmaceutical industry strategist Robin Arnold, vice president of IMS Health’s Product and Portfolio Strategy practice, will reveal insights from the company’s recent global study of pharmaceutical market growth opportunities over the next decade.
Continue reading "Finding the Future Value in Medicines - What Are The Most Promising Bets To Make?" »
We need your input. How interested are you and your company in European biopharmaceutical news and analysis?
Continue reading "Win An Apple® iPad Just By Telling Us What You Think!" »
Today's story goes like this: AstraZeneca has snared Martin Mackay to head up its global R&D organization. Mackay, of course, previously was head of Pfizer PharmaTherapeutics, responsible for Pfizer’s small molecules program and on the company’s executive leadership team.
He led half of Pfizer's R&D engine; the other half was led by Mikael Dolsten, who until today was head of Pfizer BioTherapeutics and Vaccines R&D. Before that Dolsten was head of Wyeth R&D - now he's head of Pfizer's worldwide R&D.
Following so far?
Continue reading "One From The Vaults: Our Interview With Mackay & Dolsten On Pfizer R&D" »
Even as most of pharma sees Europe as a mature market ridden with pricing pressures, Teva, by far the world's largest and most successful generics manufacturer, is unabashedly targeting the region as an opportunity.
Continue reading "Is Teva's European Strategy A Threat To Brand Manufacturers?" »